Neuronetics (STIM) Reaches New 1-Year Low at $15.52
Neuronetics Inc (NASDAQ:STIM) reached a new 52-week low on Tuesday . The company traded as low as $15.52 and last traded at $15.94, with a volume of 785 shares trading hands. The stock had previously closed at $16.00.
A number of research firms recently weighed in on STIM. Canaccord Genuity began coverage on shares of Neuronetics in a report on Tuesday, July 24th. They set a “buy” rating and a $33.00 price target for the company. JMP Securities raised their price target on shares of Neuronetics from $36.00 to $40.00 and gave the company an “outperform” rating in a report on Wednesday, August 15th. BTIG Research reaffirmed a “buy” rating and set a $33.00 price target on shares of Neuronetics in a report on Thursday, August 16th. Piper Jaffray Companies began coverage on shares of Neuronetics in a report on Monday, July 23rd. They set an “overweight” rating for the company. Finally, William Blair began coverage on shares of Neuronetics in a report on Monday, July 23rd. They set an “outperform” rating for the company. Six research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average target price of $34.50.
The company has a debt-to-equity ratio of 0.33, a current ratio of 7.63 and a quick ratio of 7.46.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Massachusetts Financial Services Co. MA acquired a new position in Neuronetics during the 2nd quarter worth $2,661,000. TD Asset Management Inc. acquired a new position in Neuronetics during the 2nd quarter worth $329,000. Emerald Mutual Fund Advisers Trust acquired a new position in Neuronetics during the 2nd quarter worth $1,570,000. Wells Fargo & Company MN acquired a new position in Neuronetics during the 2nd quarter worth $7,734,000. Finally, Victory Capital Management Inc. acquired a new position in Neuronetics during the 2nd quarter worth $133,000. 64.76% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This story was published by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.dailypolitical.com/2018/11/20/neuronetics-stim-reaches-new-1-year-low-at-15-52.html.
Neuronetics Company Profile (NASDAQ:STIM)
Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders. It offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment for adult patients with major depressive disorder. The company's NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed MRI-strength magnetic field, which induces electrical currents designed to stimulate specific areas of the brain associated with mood.
Recommended Story: What are retained earnings?
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.